Author

A. Haegert

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:differential expression· 3 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Approach:statistical model· 2 Assay:whole-exome sequencing· 2

Frequent Co-Authors

S. Volik· 4 shared B. McConeghy· 3 shared R. H. Bell· 3 shared R. Shrestha· 3 shared S. Anderson· 3 shared S. Brahmbhatt· 3 shared S. Le Bihan· 3 shared A. Churg· 2 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

S. Volik

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Patient and cell-type specific hiPSC-modeling of a truncating titin variant associated with atrial fibrillation

K. Huang, M. Ashraf, L. Rohani, Y. Luo, A. Sacayanan, H. Huang, A. Haegert, S. Volik, F. Sar, S. LeBihan, J. Liew, J. D. Roberts, G. F. Tibbits, J. M. Churko, S. Sanatani, , Z. W. Laksman

This study uses patient-derived iPSC-CMs to show that a titin truncating variant increases arrhythmia susceptibility and disrupts sarcomere structure in both atrial and ventricular tissues.

bioRxiv · Mar 2, 2023 · PreprintCell Biology

Multiomics Characterization of Potential Therapeutic Vulnerabilities in Low-grade Serous Ovarian Carcinoma

R. Shrestha, M. L. Fernandez, A. Dawson, J. Hoenisch, S. Volik, Y.-Y. Lin, S. Anderson, H. Kim, A. Haegert, S. Colborne, B. McConeghy, R. H. Bell, S. Brahmbhatt, G. E. DiMattia, S. Le Bihan, , M. S. Carey

This study uses multiomics analysis of LGSOC cell lines to identify therapeutic vulnerabilities and biomarkers for MEK inhibitor efficacy.

bioRxiv · Jun 18, 2020 · PreprintCancer Biology

Well-Differentiated Papillary Mesothelioma of the Peritoneum is Genetically Distinct from Malignant Mesothelioma

R. Shrestha, N. Nabavi, S. Volik, S. Anderson, A. Haegert, B. McConeghy, S. Brahmbhatt, R. H. Bell, S. Le Bihan, Y. Wang, C. C. C. Collins, A. Churg

This study identifies distinct genetic mutations in well-differentiated papillary mesothelioma (WDPM) that differentiate it from malignant mesothelioma.

bioRxiv · Jul 23, 2019Cancer Biology

BAP1 Haploinsufficiency Predicts a Distinct Immunogenic Class of Malignant Peritoneal Mesothelioma

R. Shrestha, N. Nabavi, Y.-Y. Lin, F. Mo, S. Anderson, S. Volik, H. H. Adomat, D. Lin, H. Xue, X. Dong, R. Shukin, R. H. Bell, B. McConeghy, A. Haegert, S. Brahmbhatt, , C. C. Collins

The paper identifies BAP1 loss as a marker for a distinct immunogenic PeM subtype, suggesting potential therapeutic targets like immune checkpoint inhibitors.

bioRxiv · Dec 13, 2018Cancer Biology